Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

- RADR® A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug classes - Phase 2 clinical trial for non-smokers with NSCLC (Non-Small Cell Lung Cancer) utilizing LP-300 in combination with chemotherapy scheduled to begin during third quarter of 2021 - Expanded potential indications for LP-184 to include ATRT pediatric brain cancers - Initiated preclinical development of new molecular entity, LP-284, in hematologic cancers - Strengthened intellectual property portfolio with filing of over 10 patent applications - Launched research and development collaboration leveraging RADR® for accelerating drug development for Actuate Therapeutics GSK3β drug candidate - Peer-reviewed studies of RADR® and LP-184 in BMC Bioinformatics and Oncotarget - Balance sheet cash at the end of 1Q'21 was $81.4 million, strengthened by follow-on offering in January of 2021